Article · 16 Sep 2026
Conference abstract
A rational approach to polymorph screening based on risk assessment: Regulatory guidelines versus extent of experimental work
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Polymorphic forms have different physicochemical properties that might have significant impact on the intended use of the material - and according to regulatory guidelines a ?polymorph screening? should be performed to ensure control of the pharmaceutical compound. However, nothing is stated about the extent of the screening - and as only imagination sets the limits for possible experimental procedures, this screening can be quite time-consuming and expensive. Thus, in many cases such a screening is postponed until later development in order to avoid unnecessary expenses. A case study is presented where 5 of 6 reported polymorphic forms were found using a very basis experimental setup. The experimental conditions were chosen in order to increase the possibilities of different crystal formations. It is demonstrated that a quite simple set-up might be sufficient in order to find the more ?probable? crystal formations - and performing such a basic polymorph screening in very early development highly reduces the risk for failure in later development.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutica Analytica Acta.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Karin Liltorp”
